FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281621340> ?p ?o ?g. }

• W4281621340 endingPage "1812" @default.
• W4281621340 startingPage "1803" @default.
• W4281621340 abstract "Cancer is life-threatening disease and being global health problems. Chemotherapy is one of the most used therapy for cancer since many years ago. Chemotherapy is also toxic for normal cell, not specific to the target cells. Consequently, chemotherapy has various side effects. Monoclonal antibody (MAb) has been developed for specific therapy which only has killing effect in cancer cells, but the survival rate of most MAbs around 20%. Therefore, in clinical practice, MAbs administration should combine with chemotherapeutic agents. For effectiveness of therapy and to minimalize adverse effects, anticancer agent with selective cytotoxic effect on target cells is needed, the immunotoxin.This study introduces a novel approach to conjugate monoclonal antibody (Cetuximab) and toxin (Puromycin), in order to selectively inhibit proliferation of triple negative breast cancer (TNBC) and to enhance the efficacy of MAb in target cells killing.Cetuximab was conjugated with Puromycin using a linker, i.e SATP (Succinimidyl-acetylthiopropionate) and tested on triple negative breast cancer cell lines (MDA-MB-231) which expressed EGFR (epidermal growth factor receptor). Cetuximab is MAb which targets EGFR. MCF-7 was used as control cells since it has low or no EGFR expression. Cell counting were conducted as viability assay at 24 hours, 48 hours, and 72 hours after treatment.The results showed significant reduction of live cells number in Conjugate 20 µg/mL cultured in MDA-MB-231 compared to MCF-7 after 24 hours, 48 hours, and 72 hours incubation. In all time period of incubation, significant reduction of MDA-MB-231 live cells number was also observed in Conjugate 20 µg/mL compared to Cetuximab 20 µg/mL.Synthesized conjugate showed its target-specific effect in TNBC and improved the efficacy of Cetuximab on TNBC. In the future, this conjugate can be a potential anticancer therapy in treating triple-negative breast cancer." @default.
• W4281621340 created "2022-06-13" @default.
• W4281621340 creator A5028371893 @default.
• W4281621340 creator A5059505601 @default.
• W4281621340 creator A5071932877 @default.
• W4281621340 date "2022-05-01" @default.
• W4281621340 modified "2023-09-30" @default.
• W4281621340 title "Conjugation of Cetuximab – Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines" @default.
• W4281621340 cites W1530940628 @default.
• W4281621340 cites W1551168702 @default.
• W4281621340 cites W1896280131 @default.
• W4281621340 cites W1987185969 @default.
• W4281621340 cites W1994143149 @default.
• W4281621340 cites W2035253718 @default.
• W4281621340 cites W2051154877 @default.
• W4281621340 cites W2061779138 @default.
• W4281621340 cites W2068125497 @default.
• W4281621340 cites W2069825136 @default.
• W4281621340 cites W2074975150 @default.
• W4281621340 cites W2100484302 @default.
• W4281621340 cites W2120323942 @default.
• W4281621340 cites W2121263556 @default.
• W4281621340 cites W2138729791 @default.
• W4281621340 cites W2143204308 @default.
• W4281621340 cites W2163694675 @default.
• W4281621340 cites W2400378778 @default.
• W4281621340 cites W2401867168 @default.
• W4281621340 cites W2402636472 @default.
• W4281621340 cites W2410223028 @default.
• W4281621340 cites W2774231122 @default.
• W4281621340 cites W2802392118 @default.
• W4281621340 cites W2905111869 @default.
• W4281621340 cites W2940742963 @default.
• W4281621340 cites W2981672088 @default.
• W4281621340 cites W3153740078 @default.
• W4281621340 doi "https://doi.org/10.31557/apjcp.2022.23.5.1803" @default.
• W4281621340 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35633567" @default.
• W4281621340 hasPublicationYear "2022" @default.
• W4281621340 type Work @default.
• W4281621340 citedByCount "0" @default.
• W4281621340 crossrefType "journal-article" @default.
• W4281621340 hasAuthorship W4281621340A5028371893 @default.
• W4281621340 hasAuthorship W4281621340A5059505601 @default.
• W4281621340 hasAuthorship W4281621340A5071932877 @default.
• W4281621340 hasBestOaLocation W42816213401 @default.
• W4281621340 hasConcept C121608353 @default.
• W4281621340 hasConcept C126322002 @default.
• W4281621340 hasConcept C153911025 @default.
• W4281621340 hasConcept C154317977 @default.
• W4281621340 hasConcept C159654299 @default.
• W4281621340 hasConcept C185592680 @default.
• W4281621340 hasConcept C202751555 @default.
• W4281621340 hasConcept C203014093 @default.
• W4281621340 hasConcept C2779200571 @default.
• W4281621340 hasConcept C2779998722 @default.
• W4281621340 hasConcept C2780110267 @default.
• W4281621340 hasConcept C3675279 @default.
• W4281621340 hasConcept C502942594 @default.
• W4281621340 hasConcept C530470458 @default.
• W4281621340 hasConcept C542903549 @default.
• W4281621340 hasConcept C55493867 @default.
• W4281621340 hasConcept C71924100 @default.
• W4281621340 hasConcept C86803240 @default.
• W4281621340 hasConcept C96232424 @default.
• W4281621340 hasConcept C98274493 @default.
• W4281621340 hasConceptScore W4281621340C121608353 @default.
• W4281621340 hasConceptScore W4281621340C126322002 @default.
• W4281621340 hasConceptScore W4281621340C153911025 @default.
• W4281621340 hasConceptScore W4281621340C154317977 @default.
• W4281621340 hasConceptScore W4281621340C159654299 @default.
• W4281621340 hasConceptScore W4281621340C185592680 @default.
• W4281621340 hasConceptScore W4281621340C202751555 @default.
• W4281621340 hasConceptScore W4281621340C203014093 @default.
• W4281621340 hasConceptScore W4281621340C2779200571 @default.
• W4281621340 hasConceptScore W4281621340C2779998722 @default.
• W4281621340 hasConceptScore W4281621340C2780110267 @default.
• W4281621340 hasConceptScore W4281621340C3675279 @default.
• W4281621340 hasConceptScore W4281621340C502942594 @default.
• W4281621340 hasConceptScore W4281621340C530470458 @default.
• W4281621340 hasConceptScore W4281621340C542903549 @default.
• W4281621340 hasConceptScore W4281621340C55493867 @default.
• W4281621340 hasConceptScore W4281621340C71924100 @default.
• W4281621340 hasConceptScore W4281621340C86803240 @default.
• W4281621340 hasConceptScore W4281621340C96232424 @default.
• W4281621340 hasConceptScore W4281621340C98274493 @default.
• W4281621340 hasIssue "5" @default.
• W4281621340 hasLocation W42816213401 @default.
• W4281621340 hasLocation W42816213402 @default.
• W4281621340 hasLocation W42816213403 @default.
• W4281621340 hasOpenAccess W4281621340 @default.
• W4281621340 hasPrimaryLocation W42816213401 @default.
• W4281621340 hasRelatedWork W2378785636 @default.
• W4281621340 hasRelatedWork W2419757242 @default.
• W4281621340 hasRelatedWork W2520018761 @default.
• W4281621340 hasRelatedWork W2910175501 @default.
• W4281621340 hasRelatedWork W3014402112 @default.
• W4281621340 hasRelatedWork W3180719608 @default.
• W4281621340 hasRelatedWork W4281621340 @default.

• next